This is a preview of subscription content, log in via an institution to check access.
References
Thonoor M, Gupta S, Solon E, et al. Pharmacokinetics of 14CSCH 56592 in rats and dogs. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 18
Graybill JR, Bocanegra R, Najvar LK, et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998 Oct; 42: 539–42
Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997 Jul; 841: 1504–7
Lutz JE, Clemons KV, Aristizabal BH, et al. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997 Jul; 41: 1558–61
Fung-Tomc JC, Bonner DP. Recent developments in pradimicin-benanomicin and triazole antibiotics. Expert Opin Investig Drugs 1997 Feb; 6: 129–45
Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo antiproliferative effects of SCH 56592 against Trypanosoma cruzi, the causative agent of Chagas disease. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 117
Parmegiani R, Cacciapuoti A, Loebenberg D, et al. In vitro activity of SCH 56592, a new antifungal agent. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 123
Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36: 2950–6
Rights and permissions
About this article
Cite this article
SCH 56592. Drugs R&D 1, 184–186 (1999). https://doi.org/10.2165/00126839-199901020-00019
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901020-00019